Search results
Century-old vaccine found to protect type 1 diabetics from infectious diseases
Medical Xpress· 2 days agoThe 18-month Phase III trial, published in iScience, was conducted late in the US pandemic when...
Trials that infected people with common colds can inform today’s COVID-19 challenge trials
Nature· 4 days agoLetter to the Editor
CureVac (NASDAQ:CVAC) Sees Large Volume Increase
ETF DAILY NEWS· 18 hours agoShares of CureVac (NASDAQ:CVAC – Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 290,327 shares traded hands during mid-day trading, a decline of 63% from the ...
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Digital Journal· 1 day agoOrganizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1 ...
TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?
The Telegraph via Yahoo News· 5 days agoIn the few minutes it takes to read this article, some 15 people are likely to have died from...
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
WKRN Nashville· 15 hours agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Iran's new president's link to COVID vaccine
Newsweek· 4 days agoNew interim Iranian President Mohammad Mokhber received scrutiny for his role in the lack of development of a domestic vaccine at the height of the...
Could FLiRT Variants Cause Another Covid-19 Surge?
Forbes· 4 days agoA new Covid-19 variant known as KP.2, or FLiRT, began to emerge in the United States in early March of this year. This dramatic rise signals that KP.2...
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
The Kansas City Star· 2 days agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it ...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and...
The Yuma Sun· 5 days agoThe efficacy of ARCT-154 against severe COVID-19 was 100 percent in healthy persons aged 18-59 and more...